Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus

Matteo Iannacone, Giovanni Sitia, Iñigo Narvaiza, Zaverio M. Ruggeri, Luca G. Guidotti

Research output: Contribution to journalArticle

Abstract

Treatment with a low dose of combined aspirin and clopidogrel, two antiplatelet drugs widely used in humans, markedly reduced the homing of virus-specific cytotoxic T lymphocytes and virus-nonspecific inflammatory leukocytes to the liver of mice acutely infected with a hepatotropic, replication-deficient, lacZ-expressing adenovirus (RAd35). Consequently, aspirin/clopidogrel-induced platelet dysfunction greatly diminished liver disease severity and inhibited viral clearance. Along with the finding that aspirin/clopidogrel caused neither bleeding nor anemia, our results suggest that antiplatelet drugs may be considered to limit excessive liver immunopathology and/or to facilitate the persistence of hepatotropic viral vectors utilized in gene therapy.

Original languageEnglish
Pages (from-to)1532-1535
Number of pages4
JournalClinical and Vaccine Immunology
Volume14
Issue number11
DOIs
Publication statusPublished - Nov 2007

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology
  • Immunology and Allergy
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus'. Together they form a unique fingerprint.

  • Cite this